Cook completes drug-coated stent trial enrolments:
This article was originally published in Clinica
Cook has completed the enrolment phase of two major multicentre clinical trials of its drug-coated coronary stent. The trials are being conducted in Asia and Europe and are designed to assess the company's paclitaxel-coated stent for reducing restenosis. Both studies are randomised and prospective, each involving 180 patient. Cook of Bloomington, Indiana, also says that a US trial of its Logic stent coated with the drug is expected to start in around two months.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.